双重抗血小板和抗凝疗方案适用于接受皮肤冠状动脉干预的妇女
Aman Kansal1, Pooja Swamy2, Jennifer A Rymer3
1Duke University, Durham, NC, USA.
Interventional cardiology clinics
|November 13, 2024
概括
透皮冠状动脉干预后,双重抗血小板治疗 (DAPT) 是至关重要的,但需要平衡出血和凝血风险. 需要更多的研究,特别是针对女性,她们在目前的心血管试验中代表性不足.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 临床试验 临床试验
背景情况:
- 双抗血小板治疗 (DAPT) 是通过皮肤冠状动脉干预 (PCI) 后的标准,以预防支架血栓形成.
- 在确定DAPT疗程和持续时间时,平衡血栓和出血风险至关重要.
- 妇女在主要的重血管化试验中代表性不足,限制了基于证据的治疗指南.
研究的目的:
- 强调在接受PCI的妇女中需要量身定制的DAPT策略.
- 为了强调女性在调查DAPT持续时间的临床试验中的代表性不足.
- 倡导专门的研究,重点关注妇女的心血管保护和出血风险.
主要方法:
- 对PCI后患者的DAPT现有文献的综述.
- 对特定人群的试验数据的分析,并注意到性别差异.
- 鉴定证据,支持在患有高出血风险或服用抗凝药的妇女中缩短DAPT.
主要成果:
- 目前的DAPT指南可能无法完全满足女性的特定需求.
- 有证据表明,缩短DAPT持续时间对女性,特别是那些出血风险较高的女性有潜在的益处.
- 妇女在关键重血管化试验中的明显代表性不足限制了最终结论.
结论:
- 需要进一步的临床试验,专门招募并专注于女性.
- 考虑性别特异性风险的个性化DAPT策略对于最佳的心血管保护至关重要.
- 需要进行更多的研究,以建立基于证据的DAPT持续时间,用于PCI后的不同女性群体.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
471
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
471
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
456
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
456
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153